Parameters/Assumptions varied | Outcome measures | Rotavirus | HPV |
---|---|---|---|
Part (a): One-way sensitivity analysis (Results for a single country, using India as a representative example) | |||
Vaccination cost per individual | ICER (I$/DALY averted) | Â | Â |
   I$5 |  | 16 | saving |
   I$25 (base-case) |  | 212 | 293 |
   I$50 |  | 457 | 710 |
Incidence of rotavirus deaths | ICER (I$/DALY averted) | Â | Â |
   80% of base-case |  | 273 | NA |
   100% (base-case) |  | 212 | NA |
   120% of base-case |  | 171 | NA |
Incidence of cervical cancer | ICER (I$/DALY averted) | Â | Â |
   80% of base-case |  | NA | 429 |
   100% (base-case) |  | NA | 293 |
   120% of base-case |  | NA | 203 |
Ratio of hospitalization to deaths associated with rotavirus | ICER (I$/DALY averted) | Â | Â |
   80% of base-case |  | 215 | NA |
   100% (base-case) |  | 212 | NA |
   120% of base-case |  | 209 | NA |
Proportion of deaths among incident cervical cancer cases | ICER (I$/DALY averted) | Â | Â |
   50% |  | NA | 460 |
   80% (base-case) |  | NA | 293 |
   90% |  | NA | 261 |
Vaccine efficacy | ICER (I$/DALY averted) | Â | Â |
   80% of base-case |  | 273 | 397 |
   base-case |  | 212 | 293 |
   120% of base-case |  | 171 | NA |
Discount rate | ICER (I$/DALY averted) | Â | Â |
   0% |  | 92 | saving |
   3% (base-case) |  | 212 | 293 |
   6% |  | 377 | 1,609 |
Treatment costs | ICER (I$/DALY averted) | Â | Â |
   75% of base-case |  | 220 | 324 |
   100% (base-case) |  | 212 | 293 |
   125% of base-case |  | 204 | 262 |
Part (b): One-way/Two-way sensitivity analysis (Aggregated results across the GAVI-eligible countries) | |||
Discount rate | Years of life saved | Â | Â |
   r = 0% |  | 15,740,674 | 6,030,585 |
   r = 3% (base-case) |  | 7,121,323 | 1,266,029 |
   r = 6% |  | 4,025,413 | 323,398 |
Discount rate | Total incremental costs, I$ | Â | Â |
   r = 0% |  | 1,137,130,971 | 66,938,177 |
   r = 3% (base-case) |  | 1,106,950,990 | 422,123,822 |
   r = 6% |  | 1,078,274,716 | 494,334,220 |
[Discount rate, type of age weight] | DALYs averted | Â | Â |
   [r = 0%, K = 0] |  | 15,767,404 | 6,191,573 |
   [r = 3%, K = 0] (base-case) |  | 7,146,859 | 1,304,426 |
   [r = 0%, K = 1] |  | 18,920,531 | 4,847,082 |
   [r = 3%, K = 1] |  | 8,121,119 | 1,148,295 |
[Discount rate, type of age weight] | No. of countries that belong to each of the cost-effectiveness categories below (at the cost of I$25 per vaccinated individual): [cost-saving, very cost-effective, cost-effective, non-cost-effective] | Â | Â |
   [r = 0%, K = 0] |  | [0,71,1,0] | [23,49,0,0] |
   [r = 3%, K = 0] (base-case) |  | [0,68,4,0] | [0,66,6,0] |
   [r = 0%, K = 1] |  | [0,71,1,0] | [23,49,0,0] |
   [r = 3%, K = 1] |  | [0,68,4,0] | [0,66,5,1] |
Part (c): Scenario analysis (or multi-way sensitivity analysis) (Aggregated results across the GAVI-eligible countries) | |||
Scenarios (defined by different combinations of different values of the following parameters, with other parameter values set at the base-case values): - Vaccination costs, I$10, I$25, I$50 - Vaccine efficacy, 80%-/+20% - Disease-specific mortality rates | No. of countries that belong to each of the cost-effectiveness categories below [cost-saving, very cost-effective, cost-effective, non-cost-effective] | Â | Â |
Scenario 1 (worst case) - Vaccination costs: I$50 - Vaccine efficacy: 80% of base-case - Mortality rates: 80% of base-case | Â | [0,62,6,4] | [0,40,25,7] |
Scenario 2 - Vaccination costs: I$25 - Vaccine efficacy: 80% of base-case - Mortality rates: 80% of base-case | Â | [0,67,4,1] | [0,60,10,2] |
Scenario 3 (base-case) - Vaccination costs: I$25 - Vaccine efficacy: base-case - Mortality rates: base-case | Â | [0,68,4,0] | [0,66,6,0] |
Scenario 4 - Vaccination costs: I$25 - Vaccine efficacy: 120% of base-case - Mortality rates: 120% of base-case | Â | [0,69,3,0] | [1,69,2,0] |
Scenario 5 (best case) - Vaccination costs: I$10 - Vaccine efficacy: 120% of base-case - Mortality rates: 120% of base-case | Â | [5,67,0,0] | [22,50,0,0] |